Some questions about the first decision of the Belgian court in the dispute between AstraZeneca and the European Commission

In the dispute between AstraZeneca and European Commission, the Belgian Court does not mention (in point IV. A. of the Decision) art. 25 of Regulation (EU) 1215/2012 Of the European Parliament and of the Council. This article states that “[i]f the parties, regardless of their domicile, have agreed that a court or the courts ofContinue reading “Some questions about the first decision of the Belgian court in the dispute between AstraZeneca and the European Commission”